Ascletis Pharma of Hangzhou was approved to start a China Phase II clinical trial of its PD-L1 candidate in HIV-1 patients. ASC22 will be tested as an immune restoration/functional cure of HIV-1. Earlier this week, Ascletis announced it had added global rights to its agreement with Suzhou Alphamab for the PD-L1 in China viral disease indications. Previously, Ascletis was testing ASC22 (envafolimab) to treat/cure chronic hepatitis B. ASC22 is a single domain PD-L1 antibody with the potential to restore immune responses in patients with chronic viral infections. More details.... Stock Symbol: (HK: 1672) Share this with colleagues: // //